101 related articles for article (PubMed ID: 31719105)
1. Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review.
Teixeira LA; Candido Dos Reis FJ
J Clin Pathol; 2020 Apr; 73(4):191-196. PubMed ID: 31719105
[TBL] [Abstract][Full Text] [Related]
2. Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer.
Hedau S; Batra M; Singh UR; Bharti AC; Ray A; Das BC
J Cancer Res Ther; 2015; 11(1):158-63. PubMed ID: 25879355
[TBL] [Abstract][Full Text] [Related]
3. Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer.
Radosa MP; Häfner N; Camara O; Diebolder H; Mothes A; Winzer H; Jansen L; Dürst M; Runnebaum IB
Int J Gynecol Cancer; 2011 Nov; 21(8):1399-406. PubMed ID: 21897273
[TBL] [Abstract][Full Text] [Related]
4. Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
Vencken PM; Reitsma W; Kriege M; Mourits MJ; de Bock GH; de Hullu JA; van Altena AM; Gaarenstroom KN; Vasen HF; Adank MA; Schmidt MK; van Beurden M; Zweemer RP; Rijcken F; Slangen BF; Burger CW; Seynaeve C
Ann Oncol; 2013 Aug; 24(8):2036-42. PubMed ID: 23543211
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
6. Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
Wang Z; Zhang J; Zhang Y; Deng Q; Liang H
Int J Mol Med; 2018 Dec; 42(6):3542-3550. PubMed ID: 30221688
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
Zhu Q; Han SX; Zhou CY; Cai MJ; Dai LP; Zhang JY
Oncotarget; 2015 May; 6(13):11575-84. PubMed ID: 25865228
[TBL] [Abstract][Full Text] [Related]
8.
Manchana T; Tantbirojn P; Pohthipornthawat N
Gynecol Oncol Rep; 2020 Aug; 33():100582. PubMed ID: 32529018
[TBL] [Abstract][Full Text] [Related]
9. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
Kotsopoulos J; Gronwald J; Karlan B; Rosen B; Huzarski T; Moller P; Lynch HT; Singer CF; Senter L; Neuhausen SL; Tung N; Eisen A; Foulkes WD; Ainsworth P; Sun P; Lubinski J; Narod SA;
Gynecol Oncol; 2018 Jul; 150(1):85-91. PubMed ID: 29793803
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East.
Siraj AK; Bu R; Iqbal K; Siraj N; Al-Haqawi W; Al-Badawi IA; Parvathareddy SK; Masoodi T; Tulbah A; Al-Dayel F; Al-Kuraya KS
Hum Mutat; 2019 Jun; 40(6):729-733. PubMed ID: 30825404
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility - A proteomics study.
Gau DM; Lesnock JL; Hood BL; Bhargava R; Sun M; Darcy K; Luthra S; Chandran U; Conrads TP; Edwards RP; Kelley JL; Krivak TC; Roy P
Cell Cycle; 2015; 14(12):1884-92. PubMed ID: 25927284
[TBL] [Abstract][Full Text] [Related]
12. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
[TBL] [Abstract][Full Text] [Related]
13. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
Thike AA; Tan PH; Ikeda M; Iqbal J
Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
[TBL] [Abstract][Full Text] [Related]
14. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of BRCA1 or BRCA2 in prostatectomy specimens is predictive of biochemical recurrence after radical prostatectomy.
Kim SH; Park WS; Yun SI; Joo J; Joung JY; Seo HK; Chung J; Lee GK; Lee KH
Histopathology; 2016 Apr; 68(5):673-9. PubMed ID: 26272590
[TBL] [Abstract][Full Text] [Related]
17. Expression of BRCA1 and BRCA2 in male breast cancers and gynecomastias.
Bernard-Gallon DJ; Déchelotte PJ; Le Corre L; Vissac-Sabatier C; Favy DA; Cravello L; De Latour MP; Bignon YJ
Anticancer Res; 2003; 23(1B):661-7. PubMed ID: 12680164
[TBL] [Abstract][Full Text] [Related]
18. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Rauh-Adelmann C; Lau KM; Sabeti N; Long JP; Mok SC; Ho SM
Mol Carcinog; 2000 Aug; 28(4):236-46. PubMed ID: 10972993
[TBL] [Abstract][Full Text] [Related]
19. Highlight: BRCA1 and BRCA2 proteins in breast cancer.
Daniel DC
Microsc Res Tech; 2002 Oct; 59(1):68-83. PubMed ID: 12242698
[TBL] [Abstract][Full Text] [Related]
20. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
